BioSpace News Archive

Relay Engages Top Cybersecurity Marketing Agency Bluetext for Cybeats Product Line

Bluetext has an enviable reputation of developing successful marketing strategies for technical products in the cybersecurity industry for large and small organizations.

July 30, 2021
·
4 min read
Lone Star Bio

Research Shows COVID-19 Victims Suffer Some Degree of Brain Damage

Research seems to concur that a person who has recovered from severe COVID-19 symptoms might experience cognitive function and memory loss later on.

July 30, 2021
·
2 min read
·
Vanessa Doctor, RN
FDA

FDA Action Alert: Sol-Gel, Eton and Pacira

The U.S. FDA is starting off August with a mix of PDUFA dates for acne products, seizure medications and a new manufacturing process for a non-opioid pain killer. Here’s a look.

July 30, 2021
·
3 min read
·
Mark Terry
Business

Gilead Expands in NC Amidst Profitable Second Quarter

As Gilead gets ready to open its doors to its new operations site in North Carolina, the company reported its product sales for the second quarter increased 21% year-over-year primarily driven by Veklury.

July 30, 2021
·
3 min read
·
Mark Terry
Drug Development

New Drug Proves to Ease the Itch for Chronic Spontaneous Urticaria

Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.

July 30, 2021
·
2 min read
·
Brandon May
Drug Development

Clinical Catch-Up: July 26-30

With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.

July 30, 2021
·
9 min read
·
Mark Terry
Policy

CDC Cracks Down on Masks Again and Warns Delta Is As infectious As Chickenpox

The U.S. Centers for Disease Control and Prevention issued a warning that the Delta variant is as infectious as chickenpox and can cause a much more severe COVID-19 infection.

July 30, 2021
·
3 min read
·
Alex Keown
Drug Development

CKD Drug Hit Phase III Endpoints Yet Rejected by FDA

Shares of Ardelyx, Inc. have fallen nearly 13% in premarket trading after the U.S. FDA rejected the company’s chronic kidney disease drug, tenapanor.

July 30, 2021
·
3 min read
·
Alex Keown
Drug Development

Vertex Hopes to Channel CF Drug Successes into Other Therapies in the Pipeline

The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.

July 30, 2021
·
2 min read
·
Brandon May
Drug Development

Alnylam’s Study on Renal Treatment Shows Promising Results In Phase III Trial

The FDA has already given its go-ahead to use lumasiran to treat PH1 and lower the urinary oxalate levels in pediatric and adult patients under the brand name OXLUMO.

July 30, 2021
·
2 min read
·
Vanessa Doctor, RN